SAM
ONCY

Strategic Asset Management’s Oncolytics Biotech ONCY Stock Holding History

Strategic Asset Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3K Hold
2,500
– – 0.01% 521
2022
Q2 		$3K Hold
2,500
– – ﹤0.01% 541
2022
Q1 		$4K Buy
+2,500
New +$4.19K 0.01% 483

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Strategic Asset Management's ONCY Position: Q3 2022 in Review

Strategic Asset Management held its Oncolytics Biotech (ONCY) position steady in Q3 2022 at 2,500 shares worth $3K. The position accounts for 0.01% of the portfolio, ranked #521.

Strategic Asset Management first reported a position in ONCY in Q1 2022 and has held it in 3 quarters since. The position peaked at $4K in Q1 2022. 36 funds tracked by Wall St. Rank hold ONCY as of Q3 2022.

  • Strategic Asset Management held 2,500 shares of Oncolytics Biotech worth $3K as of Q3 2022.
  • Strategic Asset Management left its Oncolytics Biotech share count unchanged in Q3 2022.
  • Oncolytics Biotech made up 0.01% of Strategic Asset Management's portfolio in Q3 2022, its #521 holding.
  • Strategic Asset Management first reported a position in Oncolytics Biotech in Q1 2022 and has held it in 3 quarters since.
  • Strategic Asset Management's Oncolytics Biotech position peaked at $4K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2022.

Based on Strategic Asset Management's 13F filing for Q3 2022, filed 1 Nov 2022.